

ABSTRACT

The present invention relates to novel amorphous form of 1-amino-3, 5-dimethyltricyclo[3,3,1,^{3,7}]decane hydrochloride (memantine hydrochloride), to processes for its preparation, to pharmaceutical compositions containing it and to method of treatment using the same. The amorphous form of memantine hydrochloride obtained is a known valuable agent useful in treating moderate to severe Alzheimer's disease or conditions in which N-methyl-D-aspartate (NMDA) receptor antagonist is implicated.